# OnCo record neuroblastoma-high-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/neuroblastoma-high-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "neuroblastoma-high-risk" ;
  schema:name "High-risk neuroblastoma"@en ;
  schema:alternateName "INRG high-risk neuroblastoma"@en, "Metastatic neuroblastoma"@en, "MYCN-amplified neuroblastoma"@en, "Stage 4 neuroblastoma"@en ;
  schema:description "High-risk neuroblastoma has spread widely in a child over 18 months old or carries extra copies of the MYCN gene. Treatment lasts about 18 months and uses every tool: chemotherapy, surgery, high-dose chemotherapy with stem cell rescue, radiotherapy, and the anti-GD2 antibody dinutuximab, which raised survival in ANBL0032; eflornithine, given afterwards, was approved in 2023 to lower relapse."@en ;
  schema:url <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroblastoma>, <https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/neuroblastoma-low-risk/>, <https://onco.cc/cancers/neuroblastoma-intermediate-risk/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/tandem-transplant/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/gd2/>, <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/isotretinoin/> ;
  onco:companies <https://onco.cc/companies/y-mabs/>, <https://onco.cc/companies/united-therapeutics/>, <https://onco.cc/companies/us-worldmeds/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:terms <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/adcc/>, <https://onco.cc/terms/segmental-chromosomal-aberrations/>, <https://onco.cc/terms/urinary-catecholamines/>, <https://onco.cc/terms/curie-siopen-score/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-inrg-cohn-jco-2009/>, <https://onco.cc/key-papers/paper-yu-anti-gd2-neuroblastoma-nejm-2010/>, <https://onco.cc/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-anbl0532-tandem-transplant-park-jama-2019/> ;
  onco:pipeline <https://onco.cc/trials/anbl1531/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/gd2-cart01/>, <https://onco.cc/ideas/idea-gd2-car-t-frontline-consolidation/>, <https://onco.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/drugs/eflornithine/>, <https://onco.cc/drugs/naxitamab/>, <https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/>, <https://onco.cc/technologies/tandem-transplant/> ;
  onco:standardOfCare <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/trials/anbl1531/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/drugs/busulfan/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/tandem-transplant/>, <https://onco.cc/trials/anbl0532/>, <https://onco.cc/trials/hr-nbl1/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/sargramostim/>, <https://onco.cc/drugs/aldesleukin/>, <https://onco.cc/trials/anbl0032/>, <https://onco.cc/pairings/il2-anti-gd2-caution/>, <https://onco.cc/drugs/eflornithine/>, <https://onco.cc/trials/nmtrc003/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/>, <https://onco.cc/drugs/naxitamab/>, <https://onco.cc/trials/naxitamab-201/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/gd2-cart01/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/technologies/fertility-preservation/> .